Avancerad sökning
Hittade 1 avhandling som matchar ovanstående sökkriterier.
1. Development of immunogenicity models in mice for improved risk assessment of biopharmaceuticals
Sammanfattning : The development of anti-drug-antibodies (ADA) to biopharmaceuticals, e.g. recombinant proteins including monoclonal antibodies (mAb) can lead to adverse events and clinical complications. These include reduced effect of the drug and autoimmune conditions if the administered drug is analogous to endogenous proteins. LÄS MER
Resultatsidor:
1